BioSpace News Archive

The National Foundation for Infectious Diseases issued a new framework to help leaders across many sectors—including healthcare, business, education, employer, workforce, and government—develop and implement communications that will promote vaccine acceptance and encourage the public to follow evidence-based COVID-19 prevention measures.

MediXall Group, Inc., a healthcare solutions provider, introduced the Health Karma Partner Program which was designed to provide additional multi-tiered sales channels for its subsidiary, Health Karma, to deliver its product offerings.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and year end 2020 financial results and provide a business update conference call and live audio webcast on Wednesday, March 24, 2021.

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests

MESI mTABLET ABI, device used for early detection of Peripheral Arterial Disease (PAD) by measuring Ankle-Brachial Index (ABI), was cleared for marketing and sales by the Food and Drug Administration in December 2020.

Ariadne Labs today announced the launch of the Precision Population Health initiative.

In testimony before the House Appropriations Subcommittee on Labor, Health and Human Services, and Related Agencies, March of Dimes President and CEO Stacey D. Stewart said the COVID-19 pandemic has compounded the maternal and infant health crisis and urged lawmakers to adequately fund key programs that are critical to the health of moms and babies.

Shape Memory Medical Inc. announced today that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to market its IMPEDE®-FX Embolization Plug in Japan. Cosmotec, which is a Group Company of M3 Inc https://corporate.m3.com/en/ listed on the Tokyo Stock Exchange (TYO:2413)

Company to use its novel gene editing technology to explore a potential in vivo gene therapy treatment for cystic fibrosis

The presentation will cover all key aspects of ACI’s business including a summary of the de-risked ALPHA-1062 clinical program with its accelerated path to near term FDA approval and its other market opportunities that can address areas of high unmet medical needs.